FDA Considers Range of Measures to Enhance Safety of High-Risk Excipients
This article was originally published in The Gold Sheet
Executive Summary
FDA eyes all high-risk excipients in response to DEG-tainted glycerin issue.
You may also be interested in...
Remote Site Visits Will Help US FDA Keep Reviews On Track During Remainder Of Pandemic
Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.
Revised US Approach For Parenteral Drug Leachables Could Prevent Regulatory Missteps
Broad agreement across US FDA on modified PQRI recommendations could reduce approval delays over risk of chemicals leaching into parenteral drugs.
Special Counsel Finds US FDA’s Dismissal Of Inspection Concerns Unreasonable
Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.